The Administration for Strategic Preparedness and Response May 15 announced it is launching four pharmaceutical manufacturing projects using artificial intelligence and other technologies in collaboration with the Department of Health and Human Services, the Defense Advanced Research Projects Agency and private sector organizations. The program, called “Equip-A-Pharma,” will address U.S.-based manufacturing of eight sterile injectable or oral drugs and the pharmaceutical ingredients for those medicines.   

Private sector partners conducting the projects are Battelle Memorial Institute and Aprecia, BrightPath Laboratories, Rutgers University and the Mark Cuban Cost Plus Drug Company. Each organization is expected to submit abbreviated new drug applications to the Food and Drug Administration within a year. 

Related News Articles

Headline
The AHA today submitted a letter to the Office of Science and Technology Policy in response to its request for information on regulatory reform for artificial…
Headline
The AHA Oct. 23 recommended changes to the Centers for Medicare & Medicaid Services’ Wasteful and Inappropriate Services Reduction model to address…
Headline
Comments are due Oct. 27 to the Office of Science and Technology Policy on federal regulations that hinder artificial intelligence development, deployment or…
Headline
An AHA blog published today shares how HCA Healthcare in Nashville, Tenn., has been leveraging artificial intelligence to reduce risk and improve health…
Blog
Public
Cross-industry insights and new technology are helping HCA Healthcare reduce risk, improve outcomes and lead the future of high-reliability careFor Randy Fagin…
Headline
The AHA discussed ways hospitals and health systems are leveraging artificial intelligence for care delivery in a statement submitted to the Senate…